BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11297264)

  • 1. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.
    Komatsu T; Yamazaki H; Shimada N; Nagayama S; Kawaguchi Y; Nakajima M; Yokoi T
    Clin Cancer Res; 2001 Mar; 7(3):675-81. PubMed ID: 11297264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
    Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver.
    Ozawa S; Hamada M; Murayama N; Nakajima Y; Kaniwa N; Matsumoto Y; Fukuoka M; Sawada J; Ohno Y
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):454-8. PubMed ID: 12451471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
    Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
    Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
    Ikeda K; Yoshisue K; Matsushima E; Nagayama S; Kobayashi K; Tyson CA; Chiba K; Kawaguchi Y
    Clin Cancer Res; 2000 Nov; 6(11):4409-15. PubMed ID: 11106261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rat cytochrome p450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes.
    Yamazaki H; Komatsu T; Takemoto K; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2001 Jun; 29(6):794-7. PubMed ID: 11353746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.
    Yoshisue K; Nagayama S; Shindo T; Kawaguchi Y
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1166-75. PubMed ID: 11356943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enzymatic conversion of tegafur in human tumor tissue].
    Hara Y; Sugata S; Kono A; Tanaka M
    Gan To Kagaku Ryoho; 1983 Jun; 10(6):1511-7. PubMed ID: 6409007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
    Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
    Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
    Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human cytochrome p450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes.
    Jeurissen SM; Punt A; Boersma MG; Bogaards JJ; Fiamegos YC; Schilter B; van Bladeren PJ; Cnubben NH; Rietjens IM
    Chem Res Toxicol; 2007 May; 20(5):798-806. PubMed ID: 17407329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotransformation of N-ethyl-N-(2-hydroxyethyl)perfluorooctanesulfonamide by rat liver microsomes, cytosol, and slices and by expressed rat and human cytochromes P450.
    Xu L; Krenitsky DM; Seacat AM; Butenhoff JL; Anders MW
    Chem Res Toxicol; 2004 Jun; 17(6):767-75. PubMed ID: 15206897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
    Yamamiya I; Yoshisue K; Matsushima E; Nagayama S
    Drug Metab Dispos; 2010 Aug; 38(8):1267-76. PubMed ID: 20463005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic deuterium isotope effects for 7-alkoxycoumarin O-dealkylation reactions catalyzed by human cytochromes P450 and in liver microsomes. Rate-limiting C-H bond breaking in cytochrome P450 1A2 substrate oxidation.
    Kim KH; Isin EM; Yun CH; Kim DH; Guengerich FP
    FEBS J; 2006 May; 273(10):2223-31. PubMed ID: 16649998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.
    Wang H; Bian T; Liu D; Jin T; Chen Y; Lin A; Chen C
    Pharmacogenomics; 2011 Apr; 12(4):481-92. PubMed ID: 21521021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione conjugation of trichloroethylene in human liver and kidney: kinetics and individual variation.
    Lash LH; Lipscomb JC; Putt DA; Parker JC
    Drug Metab Dispos; 1999 Mar; 27(3):351-9. PubMed ID: 10064565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correct fluorouracil (5-FU) half-life comparator for a 5-FU prodrug plus a dihydropyrimidine dehydrogenase inhibitor.
    White RM
    J Clin Oncol; 2001 Jun; 19(11):2970. PubMed ID: 11387375
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration].
    Yamada K; Hase S; Yoshimura A; Haruyama K; Katsura Y; Sameshima T; Niwa K; Ishizawa T; Shimazu H
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2333-7. PubMed ID: 2260869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.